Literature DB >> 21664400

Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves.

Beate von Teichman1, Anita Engelbrecht, Gcwalisile Zulu, Baptiste Dungu, Anne Pardini, Michele Bouloy.   

Abstract

Two modified live attenuated vaccines against the disease Rift Valley fever (RVF) have been tested for safety and efficacy in young calves. The RVF Smithburn vaccine produced in South Africa and used successfully to prevent and control the disease in endemic sub-Saharan countries was compared to the candidate vaccine RVF Clone 13. Five sero-negative calves per vaccine group were vaccinated with a single dose of each vaccine and tested for antibody response. All vaccinated calves were challenged with a highly virulent RVF virus together with five unvaccinated calves used as control of the challenge. Protection was confirmed in all vaccinated animals as they did not show any clinical signs typical of RVF. A good neutralizing antibody response was induced post-vaccination and no viraemia could be detected post-challenge in calves of both vaccine groups. All non-vaccinated control animals showed clinical symptoms of RVF, high viraemia and were euthanized. This study reported the first case of blindness in cattle resulting from virulent RVF virus infection in unvaccinated calves used as negative controls.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664400     DOI: 10.1016/j.vaccine.2011.05.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

1.  Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Jing Wu; Roberta Pugh; Pooja Kanani; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

2.  Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep.

Authors:  Myrna M Miller; Kristine E Bennett; Barbara S Drolet; Robbin Lindsay; James O Mecham; Will K Reeves; Hana M Weingartl; William C Wilson
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

3.  Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge.

Authors:  Kimberly A Dodd; Brian H Bird; Maureen G Metcalfe; Stuart T Nichol; César G Albariño
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Large-scale chromatin immunoprecipitation with promoter sequence microarray analysis of the interaction of the NSs protein of Rift Valley fever virus with regulatory DNA regions of the host genome.

Authors:  Rima Benferhat; Thibaut Josse; Benoit Albaud; David Gentien; Zeyni Mansuroglu; Vasco Marcato; Sylvie Souès; Bernard Le Bonniec; Michèle Bouloy; Eliette Bonnefoy
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 5.  Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Authors:  Kaori Terasaki; Breanna R Tercero; Shinji Makino
Journal:  Virus Res       Date:  2015-05-27       Impact factor: 3.303

6.  Potential for autoimmune pathogenesis of Rift Valley Fever virus retinitis.

Authors:  Shoshana Newman-Gerhardt; Samuel Muiruri; Eric Muchiri; Clarence J Peters; John Morrill; Alexander H Lucas; Charles H King; James Kazura; Angelle Desiree LaBeaud
Journal:  Am J Trop Med Hyg       Date:  2013-08-05       Impact factor: 2.345

7.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

8.  Application of a real-time cell analysis system in the process development and quantification of Rift Valley fever virus clone 13.

Authors:  Boitumelo Moetlhoa; Leeann Naicker; Rose Hayeshi; Anne Grobler; Nobalanda B Mokoena; Crispen Mawadza
Journal:  Access Microbiol       Date:  2020-12-17

Review 9.  Novel approaches to develop Rift Valley fever vaccines.

Authors:  Sabarish V Indran; Tetsuro Ikegami
Journal:  Front Cell Infect Microbiol       Date:  2012-10-26       Impact factor: 5.293

10.  Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle.

Authors:  William C Wilson; Bonto Faburay; Jessie D Trujillo; Izabela Ragan; Sun-Young Sunwoo; Igor Morozov; Vinay Shivanna; Aaron Balogh; Kinga Urbaniak; D Scott McVey; Dashzeveg Bold; Natasha N Gaudreault; Erin E Schirtzinger; Wenjun Ma; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.